OBJECTIVE: To explore pharmacists' beliefs, practices, and experiences regarding opioid dispensing. DESIGN: Mailed survey. SETTING: The province of Ontario. PARTICIPANTS: A total of 1011 pharmacists selected from the Ontario College of Pharmacists' registration list. MAIN OUTCOME MEASURES: Pharmacists' experiences with opioid-related adverse events (intoxication and aberrant drug-related behaviour) and their interactions with physicians. RESULTS: A total of 652 pharmacists returned the survey, for a response rate of 64%. Most (86%) reported that they were concerned about several or many of their patients who were taking opioids; 36% reported that at least 1 patient was intoxicated from opioids while visiting their pharmacies within the past year. Reasons for opioid intoxication included the patient taking more than prescribed (84%), the patient using alcohol or sedating drugs along with the opioid (69.9%), or the prescribed dose being too high (34%). Participants' most common concerns in the 3 months before the survey were patients coming in early for prescription refills, suspected double-doctoring, and requests for replacement doses for lost medication (reported frequently by 39%, 12%, and 16% of respondents, respectively). Pharmacists were concerned about physician practices, such as prescribing benzodiazepines along with opioids. Pharmacists reported difficulty in reaching physicians directly by telephone (43%), and indicated that physicians frequently did not return their calls promptly (28%). The strategies rated as most helpful for improving opioid dispensing were a provincial prescription database and opioid prescribing guidelines. CONCLUSION: Pharmacists commonly observe opioid intoxication and aberrant drug-related behaviour in their patients but have difficulty communicating their concerns to physicians. System-wide strategies are urgently needed to improve the safety of opioid prescribing and to enhance communication between physicians and pharmacists.
OBJECTIVE: To explore pharmacists' beliefs, practices, and experiences regarding opioid dispensing. DESIGN: Mailed survey. SETTING: The province of Ontario. PARTICIPANTS: A total of 1011 pharmacists selected from the Ontario College of Pharmacists' registration list. MAIN OUTCOME MEASURES: Pharmacists' experiences with opioid-related adverse events (intoxication and aberrant drug-related behaviour) and their interactions with physicians. RESULTS: A total of 652 pharmacists returned the survey, for a response rate of 64%. Most (86%) reported that they were concerned about several or many of their patients who were taking opioids; 36% reported that at least 1 patient was intoxicated from opioids while visiting their pharmacies within the past year. Reasons for opioid intoxication included the patient taking more than prescribed (84%), the patient using alcohol or sedating drugs along with the opioid (69.9%), or the prescribed dose being too high (34%). Participants' most common concerns in the 3 months before the survey were patients coming in early for prescription refills, suspected double-doctoring, and requests for replacement doses for lost medication (reported frequently by 39%, 12%, and 16% of respondents, respectively). Pharmacists were concerned about physician practices, such as prescribing benzodiazepines along with opioids. Pharmacists reported difficulty in reaching physicians directly by telephone (43%), and indicated that physicians frequently did not return their calls promptly (28%). The strategies rated as most helpful for improving opioid dispensing were a provincial prescription database and opioid prescribing guidelines. CONCLUSION: Pharmacists commonly observe opioid intoxication and aberrant drug-related behaviour in their patients but have difficulty communicating their concerns to physicians. System-wide strategies are urgently needed to improve the safety of opioid prescribing and to enhance communication between physicians and pharmacists.
Authors: Irfan A Dhalla; Muhammad M Mamdani; Marco L A Sivilotti; Alex Kopp; Omar Qureshi; David N Juurlink Journal: CMAJ Date: 2009-12-07 Impact factor: 8.262
Authors: Dennis W Raisch; Paul J Fudala; Andrew J Saxon; Robert Walsh; Paul Casadonte; Walter Ling; Bankole A Johnson; Usha Malkerneker; Patricia Ordorica; William O Williford; Mike R Sather Journal: J Am Pharm Assoc (2003) Date: 2005 Jan-Feb
Authors: Daniel M Hartung; Jennifer Hall; Sarah N Haverly; David Cameron; Lindsey Alley; Christi Hildebran; Nicole O'Kane; Deborah Cohen Journal: Pain Med Date: 2018-09-01 Impact factor: 3.750
Authors: Andrea L Murphy; Heather Phelan; Scott Haslam; Ruth Martin-Misener; Stan P Kutcher; David M Gardner Journal: Subst Abuse Treat Prev Policy Date: 2016-01-28